![]() |
|
|
Vol. 284, Issue 3, 1074-1081, March 1998
Department of Pharmaceutical Sciences (G.L., R.D., R.K.V., N.W.,
A.L.), UCL, Pharmacokinetics and Metabolism Unit-FATC, Laboratory of
Mass Spectrometry, Brussels, Belgium, and
Experimental Immunology Unit
(D.L.), UCL, Brussels, Belgium
In order to mediate their effects, cyclosporin A and FK-506 must each
bind with high affinity to a cytosolic target protein that belongs to
the immunophilin group. FK-506 forms complexes with the FK-506 binding
protein FKBP, mainly FKBP-12, and these complexes possess
immunosuppressive activity through their ability to interact with
another target, the abundant serine threonine phosphatase calcineurin.
Evaluating the immunosuppressive activities of the FK-506 metabolites
by comparing them with known immunosuppressive agents via
mixed lymphocyte reaction is of clinical importance because some
metabolites may retain the pharmacological activity of the parent drug
or exhibit cytotoxic effects. FK-506 is metabolized by the cytochrome
P-450-dependent mixed-function oxygenase system in different
animal species, and we are reporting the isolation from pig liver
microsomes, and the identification by electrospray ms-ms, of the FK-506
C19-C20 epoxide metabolite. We found that this
new metabolite exhibits reduced in vitro immunosuppressive activity compared with FK-506 and has approximately the same
immunosuppressive potency as other known immunosuppressive drugs, such
as cyclosporin A and IMM-125, a hydroxyethyl derivative of
D-serine cyclosporin A. We were able to demonstrate that
after incubation of the FK-506 metabolite in human mixed lymphocyte
reaction cultures for 6 days, the compound was stable under the
conditions used for cell culture as evidenced by electrospray-ms data.
A weak direct cytotoxic effect (<30% cell death) was observed only at
the highest concentrations (2500 and 5000 ng/ml), which shows that the
mixed lymphocyte reaction inhibition cannot be due to a toxic effect.